Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Melike Ozcelik"'
Autor:
Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Burcin Cakan Demirel, Omer Acar, Sercan Aksoy, Naziyet Kose Baytemur, Elif Sahin, Devrim Cabuk, Gul Basaran, Semra Paydas, Arzu Yaren, Deniz Can Guven, Atike Pinar Erdogan, Umut Demirci, Alper Yasar, İbrahim Vedat Bayoglu, Mutlu Hizal, Burcu Gulbagci, Nail Paksoy, Sena Ece Davarci, Funda Yilmaz, Ozlem Dogan, Sibel Oyucu Orhan, Erkan Kayikcioglu, Ali Aytac, Merve Keskinkilic, Eda Eylemer Mocan, Olcun Umit Unal, Esra Aydin, Hakan Yucel, Deniz Isik, Onder Eren, Basak Oyan Uluc, Melike Ozcelik, Ilhan Hacibekiroglu, Adnan Aydiner, Hacer Demir, Berna Oksuzoglu, Ebru Cilbir, Erdem Cubukcu, Bulent Cetin, Esin Oktay, Cihan Erol, Sadi Kerem Okutur, Nilgun Yildirim, Ali Alkan, Fatih Selcukbiricik, Asude Aksoy, Yusuf Karakas, Gulhan Ozkanli, Berna Bozkurt Duman, Dincer Aydin, Ozgecan Dulgar, Muhammed Muhiddin Er, Fatih Teker, Tugba Yavuzsen, Musa Baris Aykan, Ali Inal, Yakup Iriagac, Nurhan Onal Kalkan, Murat Keser, Teoman Sakalar, Serkan Menekse, Engin Kut, Burak Bilgin, Muge Karaoglanoglu, Veli Sunar, Ozlem Ozdemir, Nazim Serdar Turhal, Nuri Karadurmus, Bulent Yalcin, Mehmet Ali Nahit Sendur
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4603b0dea982cdc71feb0666817cb5
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:462-465
Introduction Nivolumab is a human immunoglobulin G4 monoclonal antibody that inhibits programmed cell death-1 activity by binding to the programmed cell death-1 receptors. Cancer cells express increased number of programmed cell death-1 ligands and t
Autor:
Ayse Irem Yasin, Sabin Göktas Aydin, Bilge Sümbül, Lokman Koral, Melih Şimşek, Çağlayan Geredeli, Akın Öztürk, Perihan Perkin, Derya Demirtaş, Engin Erdemoglu, İlhan Hacıbekiroglu, Emre Çakır, Eda Tanrıkulu, Ezgi Çoban, Melike Ozcelik, Sinemis Çelik, Fatih Teker, Asude Aksoy, Sedat T Fırat, Ömer Tekin, Ziya Kalkan, Orhan Türken, Bala B Oven, Faysal Dane, Ahmet Bilici, Abdurrahman Isıkdogan, Mesut Seker, Hacı M Türk, Mahmut Gümüş
Publikováno v:
Future Oncology
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce80e141c2165fb933786d2089960e2a
https://hdl.handle.net/11424/286170
https://hdl.handle.net/11424/286170
Autor:
Tugba Kizilboga Akgun, Fikret Ezberci, Melike Ozcelik, Sezin Canbek, Elifnaz Celik, Ebru Zemheri, Levent Doganay, Nihat Bugra Agaoglu, Gizem Alkurt, Jale Yıldız, Feruze Yilmaz Enc, Gözde Kir, Izzet Mehmet Akcay, Ali Kılıç, Gizem Dinler Doganay
Publikováno v:
International Journal of Cancer. 148:285-295
Inherited pathogenic variants account for 5% to 10% of all breast cancer (BC) and colorectal cancer (CRC) cases. Here, we sought to profile the pathogenic variants in 25 cancer susceptibility genes in Turkish population. Germline pathogenic variants
Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
Autor:
Mustafa Degirmenci, Melike Ozcelik, Mehmet Aliustaoglu, Mahmut Gumus, Heves Sürmeli, Deniz Tataroğlu, Mevlude Inanc, Ozlem Ercelep
Publikováno v:
Turkish Journal of Obstetrics and Gynecology
Turkish Journal of Obstetrics and Gynecology, Vol 17, Iss 2, Pp 123-127 (2020)
Turkish Journal of Obstetrics and Gynecology, Vol 17, Iss 2, Pp 123-127 (2020)
Objective To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer. Materials and methods Data o
Autor:
Elvina Almuradova, irem öner, Murat Ayhan, Emre Yekedüz, Esma Turkmen Bekmez, Devrim Cabuk, Ahmet Gulmez, miraç özen, Melike Ozcelik, elif şenocak taşçı, Murat Dincer, Turgut Kaçan, Özgecan Dülgar, Ozlem Ozdemir, Melek Karakurt Eryilmaz, Ozkan Alan, Hasan Cagri Yildirim, Ebru Cilbir, Berna Öksüzoğlu, Serdar Turhal, Tugba Basoglu, Nazan Demir, Naziye Ak, Yusuf Karakas, Mutlu Dogan, Deniz Tataroğlu Özyükseler, Ali Inal, Abdullah Sakin, çağlar ünal, Ilhan Hacibekiroglu, Gulhan Ipek Deniz, Perran Fulden Yumuk, Dilek Erdem, Mehmet Ali Nahit Sendur, Cihan Erol, Suayib Yalcin, nelihan doğan, Bulent Karabulut, Ercan Ozden, Abdilkerim Oyman, Ozlem Er, Semra Paydas, Derya Kivrak Salim, Asude Aksoy
PurposeNeoadjuvant chemotherapy(NACT) in gastroesophageal junction(GEJ) and gastric cancer(GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT in order to compare the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6d1eb63553c52367c6638ae07976dfd
https://doi.org/10.21203/rs.3.rs-884239/v1
https://doi.org/10.21203/rs.3.rs-884239/v1
Autor:
Naziye Ak, Saban Secmeler, Abdilkerim Oyman, Ahmet Kucukarda, Ilker Nihat Okten, Ilkay Gulturk, Ilhan Hacibekiroglu, Deniz Tataroğlu Özyükseler, Okan Avci, Adnan Aydiner, Muhammed Mustafa Atci, Tugba Basoglu, İbrahim Çil, Nail Paksoy, Emre Cakir, Ferhat Ferhatoglu, Arif Hakan Onder, Murat Ayhan, Melike Ozcelik, Baran Akagunduz
Publikováno v:
Tumori. 108(1)
Introduction: Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer. However, clinical trials underrepresent pa
Autor:
Elif Şenocak Taşçi, Basak Oyan, Ozlem Sonmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Irem Oner, Havva Yesil Cinkir, Melek Karakurt Eryılmaz, Onur Yazdan Balçık, Nail Paksoy, Derya Kivrak Salim, Mirac Özen, Melike Ozcelik, Ali Arican, Ali Inal, Baran Akagunduz, Dinçer Aydın, Leyla Ozer, Nazim Serdar Turhal, Ahmet Gulmez
Publikováno v:
Journal of Clinical Oncology. 40:202-202
202 Background: The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib (Reg) revealed promising results by improving overall survival compared to best supportive care. However, in real-
Autor:
Sinan Koca, Dincer Aydin, Melike Ozcelik, Faysal Dane, Mehmet Besiroglu, Bekir Hacioglu, Mustafa Karaca, Gamze Gokoz Dogu, Zeynep Oruç, Mehmet Bilici, Nihal B Kaplan
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(3)
Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. T
Publikováno v:
Northern Clinics of Istanbul
OBJECTIVE: Tumor size, along with other clinicopathological characteristics, has a prognostic role in breast cancer. Recurrence risk tends to rise as tumor size increases. Early T-stage portends a good prognosis. We aimed to investigate the recurrenc